Concomitant active tuberculosis prolongs survival in non-small cell lung cancer: A study in a tuberculosis-endemic country

Chih Hsi Kuo, Chun Yu Lo, Fu Tsai Chung, Kang Yun Lee, Shu Min Lin, Chun Hua Wang, Chih Chen Heh, Hao Cheng Chen, Han Pin Kuo

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background: Adjuvant tumor cell vaccine with chemotherapy against non-small cell lung cancer (NSCLC) shows limited clinical response. Whether it provokes effective cellular immunity in tumor microenvironment is questionable. Concomitant active tuberculosis in NSCLC (TBLC) resembles locoregional immunotherapy of tumor cell vaccine; thus, maximally enriches effective anti-tumor immunity. This study compares the survival and immunological cell profile in TBLC over NSCLC alone. Methods: Retrospective review of NSCLC patients within 1-year-period of 2007 and follow-up till 2010. Results: A total 276 NSCLC patients were included. The median survival of TBLC is longer than those of NSCLC alone (11.6 vs. 8.8 month, p

Original languageEnglish
Article numbere33226
JournalPLoS One
Volume7
Issue number3
DOIs
Publication statusPublished - Mar 16 2012
Externally publishedYes

Fingerprint

lung neoplasms
tuberculosis
Non-Small Cell Lung Carcinoma
Tumors
Tuberculosis
Cells
Survival
Cancer Vaccines
Vaccines
cells
Chemotherapy
Tumor Microenvironment
vaccines
neoplasms
immunotherapy
Cellular Immunity
Immunotherapy
Immunity
Cell Survival
cell-mediated immunity

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Concomitant active tuberculosis prolongs survival in non-small cell lung cancer : A study in a tuberculosis-endemic country. / Kuo, Chih Hsi; Lo, Chun Yu; Chung, Fu Tsai; Lee, Kang Yun; Lin, Shu Min; Wang, Chun Hua; Heh, Chih Chen; Chen, Hao Cheng; Kuo, Han Pin.

In: PLoS One, Vol. 7, No. 3, e33226, 16.03.2012.

Research output: Contribution to journalArticle

Kuo, Chih Hsi ; Lo, Chun Yu ; Chung, Fu Tsai ; Lee, Kang Yun ; Lin, Shu Min ; Wang, Chun Hua ; Heh, Chih Chen ; Chen, Hao Cheng ; Kuo, Han Pin. / Concomitant active tuberculosis prolongs survival in non-small cell lung cancer : A study in a tuberculosis-endemic country. In: PLoS One. 2012 ; Vol. 7, No. 3.
@article{c62dd2dd4e894783a0f34a7eb32b6306,
title = "Concomitant active tuberculosis prolongs survival in non-small cell lung cancer: A study in a tuberculosis-endemic country",
abstract = "Background: Adjuvant tumor cell vaccine with chemotherapy against non-small cell lung cancer (NSCLC) shows limited clinical response. Whether it provokes effective cellular immunity in tumor microenvironment is questionable. Concomitant active tuberculosis in NSCLC (TBLC) resembles locoregional immunotherapy of tumor cell vaccine; thus, maximally enriches effective anti-tumor immunity. This study compares the survival and immunological cell profile in TBLC over NSCLC alone. Methods: Retrospective review of NSCLC patients within 1-year-period of 2007 and follow-up till 2010. Results: A total 276 NSCLC patients were included. The median survival of TBLC is longer than those of NSCLC alone (11.6 vs. 8.8 month, p",
author = "Kuo, {Chih Hsi} and Lo, {Chun Yu} and Chung, {Fu Tsai} and Lee, {Kang Yun} and Lin, {Shu Min} and Wang, {Chun Hua} and Heh, {Chih Chen} and Chen, {Hao Cheng} and Kuo, {Han Pin}",
year = "2012",
month = "3",
day = "16",
doi = "10.1371/journal.pone.0033226",
language = "English",
volume = "7",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "3",

}

TY - JOUR

T1 - Concomitant active tuberculosis prolongs survival in non-small cell lung cancer

T2 - A study in a tuberculosis-endemic country

AU - Kuo, Chih Hsi

AU - Lo, Chun Yu

AU - Chung, Fu Tsai

AU - Lee, Kang Yun

AU - Lin, Shu Min

AU - Wang, Chun Hua

AU - Heh, Chih Chen

AU - Chen, Hao Cheng

AU - Kuo, Han Pin

PY - 2012/3/16

Y1 - 2012/3/16

N2 - Background: Adjuvant tumor cell vaccine with chemotherapy against non-small cell lung cancer (NSCLC) shows limited clinical response. Whether it provokes effective cellular immunity in tumor microenvironment is questionable. Concomitant active tuberculosis in NSCLC (TBLC) resembles locoregional immunotherapy of tumor cell vaccine; thus, maximally enriches effective anti-tumor immunity. This study compares the survival and immunological cell profile in TBLC over NSCLC alone. Methods: Retrospective review of NSCLC patients within 1-year-period of 2007 and follow-up till 2010. Results: A total 276 NSCLC patients were included. The median survival of TBLC is longer than those of NSCLC alone (11.6 vs. 8.8 month, p

AB - Background: Adjuvant tumor cell vaccine with chemotherapy against non-small cell lung cancer (NSCLC) shows limited clinical response. Whether it provokes effective cellular immunity in tumor microenvironment is questionable. Concomitant active tuberculosis in NSCLC (TBLC) resembles locoregional immunotherapy of tumor cell vaccine; thus, maximally enriches effective anti-tumor immunity. This study compares the survival and immunological cell profile in TBLC over NSCLC alone. Methods: Retrospective review of NSCLC patients within 1-year-period of 2007 and follow-up till 2010. Results: A total 276 NSCLC patients were included. The median survival of TBLC is longer than those of NSCLC alone (11.6 vs. 8.8 month, p

UR - http://www.scopus.com/inward/record.url?scp=84863348587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863348587&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0033226

DO - 10.1371/journal.pone.0033226

M3 - Article

C2 - 22438899

AN - SCOPUS:84863348587

VL - 7

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 3

M1 - e33226

ER -